BTK and B-cell non-Hodgkin lymphoma: Discussion of all these targets is beyond the scope of this review article, but one class of therapy, small molecular inhibitor of Bruton tyrosine kinase (BTK), an essential component for BCR signaling, has gained a lot of attention in recent years as a treatment for various B-cell lymphomas.